Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Belaperidone (Knoll AG).

M D Tricklebank1

  • 1Nervous System Research, Novartis Pharma AG, CH-4002 Basel, Switzerland. mark.tricklebank@pharma.Novartis.com

Idrugs : the Investigational Drugs Journal
|August 19, 2005
PubMed
Summary

Belaperidone, an atypical antipsychotic, shows promise for schizophrenia treatment. It effectively reversed neuronal inhibition in rats, demonstrating potent dopamine D4 receptor antagonism with low muscarinic affinity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Shifting brain inhibitory balance and connectivity of the prefrontal cortex of adults with autism spectrum disorder.

Translational psychiatry·2017
Same author

Innovative solutions to novel drug development in mental health.

Neuroscience and biobehavioral reviews·2013
Same author

Subtypes of 5-HT receptors.

Journal of psychopharmacology (Oxford, England)·2011
Same author

The pharmacological sensitivity of a touchscreen-based visual discrimination task in the rat using simple and perceptually challenging stimuli.

Psychopharmacology·2011
Same author

JP-1302: a new tool to shed light on the roles of alpha2C-adrenoceptors in brain.

British journal of pharmacology·2007
Same author

Substitution for PCP, disruption of prepulse inhibition and hyperactivity induced by N-methyl-D-aspartate receptor antagonists: preferential involvement of the NR2B rather than NR2A subunit.

Behavioural pharmacology·2003

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Schizophrenia treatment remains challenging, particularly for patients with difficult-to-treat conditions.
  • Atypical antipsychotics offer improved profiles over older agents, but novel mechanisms are sought.

Purpose of the Study:

  • To evaluate belaperidone, a novel antipsychotic agent, for its potential in treating schizophrenia.
  • To characterize the preclinical pharmacological profile of belaperidone.

Main Methods:

  • In vivo studies in rats assessed belaperidone's effect on dopaminergic neuron firing rates.
  • Receptor binding assays determined affinities for 5-HT2, dopamine D2 and D4, and muscarinic receptors.

Main Results:

  • Belaperidone reversed quinpirole-induced inhibition of substantia nigra dopaminergic neuron firing in rats (ED50 = 1.66 mg/kg).
  • It demonstrated selective antagonism of dopamine D4 receptors (Ki = 3.1 nM) over D2 receptors (Ki = 105 nM) and high 5-HT2 affinity (Ki = 3.3 nM).
  • Belaperidone exhibited very low muscarinic affinity (Ki > 200 nM) and did not induce catalepsy.

Conclusions:

  • Belaperidone exhibits a preclinical antipsychotic profile with potent D4 and 5-HT2 receptor antagonism and low muscarinic activity.
  • Its efficacy and safety profile suggest potential as a novel treatment for schizophrenia, especially in treatment-resistant cases.

Related Experiment Videos